Skip to content

US · ANIP · DRUG MANUFACTURERS - SPECIALTY & GENERIC

ANI Pharmaceuticals, Inc. (ANIP) intrinsic value and stock valuation

$68.55as of 2026-11-21 · Mkt cap 1.82B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ANI Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values ANIP with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ANIP’s statements →

ANI Pharmaceuticals, Inc. Graham Number

Graham Number: $48.68d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Baudette, MN 56623 anipharmaceuticals.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$883.4M+33.5% 5y CAGRd
20112025
Net income
$78.3M
20112025
Free cash flow
$150.9M
20112025
Total equity
$540.7M+22.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$883.4M$614.4M$486.8M$316.4M$216.1M
Operating income$81.2M$580K$47M-$-35.28M-$-39.79M
Net income$78.3M-$-18.52M$18.8M-$-47.9M-$-42.6M
EPSd$3.69M-$-958.59K$1.03M-$-2.95M-$-3.38M
Operating cash flow$185.2M$64M$119M-$-31.2M$3.32M
Capital expenditure-$-34.32M-$-16.95M-$-18.51M-$-16.45M-$-23.64M
Free cash flow$150.9M$47.1M$100.5M-$-47.66M-$-20.32M
Total assets$1.44B$1.28B$904.4M$760.1M$771.6M
Total debt$325.2M$624.1M$285.7M$286.5M$287.4M
Net debt$39.6M$479.2M$64.6M$238.3M$187.1M
Total equity$540.7M$428.5M$457.6M$338.5M$358.7M
Cash and short-term investments$285.6M$151.2M$221.1M$48.2M$100.3M
Income statement
20252024202320222021
Revenue$883.4M$614.4M$486.8M$316.4M$216.1M
Cost of revenue$432.7M$250.2M$181.5M$138.8M$100.6M
Gross profit$450.6M$364.2M$305.3M$177.6M$115.5M
Research and development expenses$51.7M$44.6M$34.3M$22.3M$11.4M
Selling, general and administrative expenses$317.8M$249.6M$161.7M$124M$84.3M
Other expenses$0.00$69.4M$62.4M$66.5M$59.7M
Operating expenses$369.4M$363.6M$258.3M$212.9M$155.3M
Cost and expenses$802.1M$613.8M$439.9M$351.7M$255.9M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$20.1M$17.6M$26.9M$28.1M$11.9M
Depreciation and amortization$91.4M$67.7M$59.8M$59.7M$47.3M
Ebitda$207.3M$63.1M$106.6M$25M$3.12M
Operating income$81.2M$580K$47M-$-35.28M-$-39.79M
Total other income/expenses, net$14.6M-$-22.8M-$-27.1M-$-27.38M-$-16.27M
Income before tax$95.8M-$-22.21M$19.9M-$-62.66M-$-56.06M
Income tax expense$17.5M-$-3.69M$1.09M-$-14.77M-$-13.46M
Net income$78.3M-$-18.52M$18.8M-$-47.9M-$-42.6M
Weighted average shares outstanding$20.1M$19.3M$18M$16.3M$12.6M
Weighted average diluted shares outstanding$21.2M$19.3M$18.2M$16.3M$12.6M
Balance sheet
20252024202320222021
Cash and short-term investments$285.6M$151.2M$221.1M$48.2M$100.3M
Net receivables$281.1M$221.7M$162.1M$165.4M$128.5M
Inventory$143.1M$136.8M$111.2M$105.4M$81.7M
Total current assets$753.1M$527.7M$519.8M$344.3M$321.8M
Property, plant and equipment, net$62.5M$56.9M$44.6M$43.3M$52.7M
Goodwill and intangible assets$542M$601.8M$237.2M$279.9M$322M
Long-term investments$0.00$0.00$6.2M$0.00$5M
Total non-current assets$687.3M$756M$384.6M$415.8M$449.8M
Total assets$1.44B$1.28B$904.4M$760.1M$771.6M
Accounts payable$62.6M$45.7M$36.7M$29.3M$23M
Short-term debt$17.3M$9.17M$850K$850K$850K
Deferred revenue$0.00$0.00$0.00$0.00$90K
Total current liabilities$278.1M$193.7M$145.5M$99.4M$87.5M
Long-term debt$307.9M$614.9M$284.8M$285.7M$286.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00-$-9.49M
Total non-current liabilities$621.5M$661.5M$301.4M$322.1M$325.3M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$899.7M$855.2M$446.8M$421.6M$412.9M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-23.1M-$-100.28M-$-80.13M-$-97.29M-$-47.77M
Accumulated other comprehensive income (loss)$1.03M$5.34M$8.86M$12.2M-$-3.06M
Total equity$540.7M$428.5M$457.6M$338.5M$358.7M
Total investments$0.00$6.31M$6.2M$0.00$5M
Total debt$325.2M$624.1M$285.7M$286.5M$287.4M
Net debt$39.6M$479.2M$64.6M$238.3M$187.1M
Cash flow statement
20252024202320222021
Net income$78.3M-$-18.52M$18.8M-$-47.9M-$-42.6M
Depreciation and amortization$91.4M$67.7M$59.8M$59.7M$47.3M
Stock-based compensation$37.9M$29.3M$20.7M$14.6M$10.5M
Change in working capital-$-7.12M-$-11.19M$24.9M-$-51.3M-$-80K
Accounts receivable-$-58.53M-$-21.09M$3.36M-$-36.91M-$-5.55M
Inventory-$-5.96M-$-21.29M-$-5.84M-$-23.63M$3.22M
Accounts payable$15.2M$480K$7.55M$5.04M$10.2M
Net cash provided by operating activities$185.2M$64M$119M-$-31.2M$3.32M
Investments in property, plant and equipment-$-13.84M-$-16.24M-$-8.87M-$-8.88M-$-2.56M
Acquisitions, net$0.00-$-401.28M$0.00-$-30K-$-84.49M
Net cash used for investing activities-$-34.32M-$-404.72M-$-18.51M-$-15.74M-$-105.48M
Common stock issued$13.6M$0.00$80.6M$0.00$69.6M
Common stock repurchased-$-12.21M-$-10.96M-$-4.99M-$-1.96M-$-890K
Dividends paid-$-1.16M-$-1.62M-$-1.62M-$-1.62M-$-190K
Net cash used for financing activities-$-9.94M$264.9M$67.4M-$-5.13M$194.6M
Net change in cash$140.7M-$-76.23M$167.9M-$-52.07M$92.4M
Cash at end of period$285.6M$144.9M$221.1M$53.2M$105.3M
Operating cash flow$185.2M$64M$119M-$-31.2M$3.32M
Capital expenditure-$-34.32M-$-16.95M-$-18.51M-$-16.45M-$-23.64M
Free cash flow$150.9M$47.1M$100.5M-$-47.66M-$-20.32M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ANI Pharmaceuticals, Inc.

        ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

        CEO
        Nikhil Lalwani
        Employees
        970
        Beta
        0.43

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of ANI Pharmaceuticals, Inc. (ANIP)?

        ANI Pharmaceuticals, Inc. (ANIP) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ANIP undervalued?

        ANIP trades at a price of $68.55 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.